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Abstract
To determine the role of innate immune responses in controlling influenza A virus replication, rhesus macaques (RM) were
administered pegylated IFN-alpha prior to virus challenge. Systemic and mucosal pegylated IFN-alpha administration
induced expression of the interferon-stimulated genes (ISG) MxA and OAS in the airways. RM treated with IFN-alpha
24 hours prior to influenza virus challenge had significantly lower peak vRNA levels in the trachea compared to untreated
animals. In addition to blunting viral replication, IFN-alpha treatment minimized the weight loss and spike in body
temperature after influenza infection of RM. These results confirm the importance of IFN-alpha induced innate immune
responses in the rapid control of influenza A virus replication in primates.
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Introduction
Seasonal influenza is an acute respiratory tract disease of
humans that is highly contagious and results in high morbidity
and mortality each year, mainly among the young, elderly, and
immune-compromised [1]. Influenza A virus replication peaks
within the first few days of infection and is cleared 5–7 days after
infection, well before the generation of virus-specific adaptive
immune responses [2]. Thus, it is unlikely that the adaptive
immune response plays an important role in clearing the virus.
In contrast, the innate immune response, specifically the
expression of type I interferons (IFN), is induced within hours
of infection and the peak of IFN-alpha-induced gene expression
temporally correlates with the decrease in viral replication in
humans [3].
Type I IFNs induce the expression of hundreds of antiviral
effector molecules [4], which have been shown to play important
roles in blocking virus replication, though the specific interferon-
stimulated genes involved varies with the virus [5]. Administering
Type I IFN prior to influenza A virus inoculation reduces virus
replication in the upper respiratory tract mice and ferrets [6,7,8],
however, a role for IFN-alpha in controlling influenza virus
replication in humans or the lower respiratory tract of mice and
ferrets has never been demonstrated. Due to the relatively close
phylogenetic relationship of nonhuman primates to humans,
macaques are excellent models of the human immune and
respiratory systems. Here we report that the administration of
IFN-alpha to rhesus macaques prior to Influenza A virus
inoculation significantly decreases clinical signs of infection and
reduces virus replication in the lower respiratory tract.
Methods
Ethics Statement/Animals
All animals used in this study were adult rhesus macaques
(Macaca mulatta) housed at the California National Primate
Research Center in accordance with the recommendations of the
Association for Assessment and Accreditation of Laboratory
Animal Care International Standards and with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The Institutional Animal Use
and Care Committee of the University of California, Davis,
approved these experiments (Protocol #13022). For blood
collection, animals were anesthetized with 10 mg/kg ketamine
hydrochloride (Park-Davis) injected i.m. For virus inoculation
and respiratory secretion sample collection, animals were
additionally anesthetized with 15–30 mg/kg Domitor (Orion
Pharma) injected i.m., and anesthesia was reversed with 0.07–
0.15 mg/kg Antisedan (Pfizer Animal Health) injected i.m. All
efforts were made to minimize suffering. Details of animal welfare
and steps taken to ameliorate suffering were in accordance with
the recommendations of the Weatherall report, ‘‘The use of non-
human primates in research’’. Animals were housed in an air-
conditioned facility with an ambient temperature of 21–25uC, a
relative humidity of 40%–60% and a 12 h light/dark cycle.
Animals were individually housed in suspended stainless steel
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diet. Fresh fruit was provided once daily and water was freely
available at all times.
Virus Stocks
The human influenza A virus isolate used in this study, A/
Memphis/7/2001 (H1N1), was generously provide by Richard
Webby at the St. Jude’s Children Hospital, Memphis, TN. This
isolate was isolated on MDCK and was not passaged further prior
to expansion in MDCK cells (American Type Culture Collection,
Manassas, VA) to produce the virus stock used for animal
inoculations. The virus stock had a titer of 10
6.5 TCID50/ml on
MDCK cells using the method of Reed and Muench [9].
Administration of IFN-alpha and influenza A virus
inoculation
Animals were administered PegasysH (pegylated IFN-alpha 2a)
intratracheally, intranasally, and intramuscularly with doses of
25 ug in 1 mL, 25 ug in 1 mL, and 50 ug in 0.5 mL, respectively.
All dilutions were done in PBS. The intranasal/intratracheal/
conjunctival influenza A virus inoculation procedureand the
respiratory secretion sample collection procedure have been
previously described [10]. Some animals were treated with IFN-
alpha 24 hours before inoculation with 1 ml of the virus stock
instilled into the trachea, 1 ml of virus stock dripped intranasally,
and a drop of virus stock in each conjunctiva. Tracheal aspirate
and blood samples were collected on days 28, 24, 0 (blood only),
1, 2, 3, 7, 14, and 28 (blood only) relative to the day of influenza A
virus challenge.
Titration of viral RNA in respiratory secretions
The concentration of virion-associated RNA (vRNA) in
respiratory secretions was determined by RT-PCR as previously
described [10].
Tracheal sample cytokine mRNA expression levels
The method for assessment of host gene expression in tracheal
secretions has been published [10]. Briefly, total RNA was
isolated from the cellular pellets with TRIzolH (Invitrogen)
according to manufacturer’s instructions. RNA samples were
DNase-treated and cDNA was prepared using random hexamer
primers (Amersham-Pharmcia Biotech Inc.) and SuperScript III
reverse transcriptase (Invitrogen). Cytokine mRNA levels were
determined by RT-PCR as described previously [11,12]. The
GAPDH housekeeping gene and the target gene from each
sample were run in parallel in the same plate. The reaction was
carried out in a 96-well optical plate (Applied Biosystems) in a
25 ml reaction volume containing 5 mlc D N Ap l u s2 0 ml
Mastermix (Applied Biosystems). All sequences were amplified
using the 7900 default amplification program. The results were
analyzed with the SDS 7900 system software, version 2.1
(Applied Biosystems). Cytokine mRNA expression levels were
calculated from normalized DCT values. CT values correspond to
the cycle number at which the fluorescence due to enrichment of
the PCR product reaches significant levels above the background
fluorescence (threshold). In this analysis, the CT value for the
housekeeping gene (GAPDH) is subtracted from the CT value of
the target (cytokine) gene (DCT). In general, the DCT value for
the influenza A-infected sample is then subtracted from the pre-
infection DCT value (DDCT). Assuming that the target gene
(cytokine) and the reference gene (GAPDH) are amplified with
the same efficiency (data not shown), the increase in cytokine
mRNA levels in test samples is then calculated as follows:
increase=2
2DDC
T (user bulletin no. 2, ABI Prism 7700 Sequence
Detection System: Applied Biosystems). Cytokine mRNA levels
are expressed as the increase or decrease relative to the level for
that cytokine in the individual monkey’s pretreatment secretion
sample. Because the mRNA expression level of housekeeping
genes such as GAPDH can change under activating conditions,
we were careful to use the same input amount of RNA for
experimental samples in the PCR reactions. Regardless of the
sample was collected the same input amount of RNA consistently
resulted in similar PCR amplification (CT) values for GAPDH.
Therefore, GAPDH expression in trachea was not differentially
regulated among the animals in this study.
Statistical Analysis
Statistics are reported as the mean and the standard error of the
mean for each group using Prism 5.0a software (GraphPad) and
data are presented as the probability and test used for analysis.
Differences in vRNA levels, body temperature, and body weight in
the treated and untreated animals after influenza virus inoculation
were compared using a one-tailed t-test.
Figure 1. Innate antiviral responses induced in blood and lungs of rhesus macaques by exogenous IFN-alpha administration.
Responses are represented as fold increase in specific gene mRNA levels as compared to pre-exposure mRNA levels isolated from an average of each
animal’s matched pre-exposure samples. A. Average MxA and OAS mRNA expression from PBMC (n=6). B. Average MxA and OAS expression in the
cell pellet from tracheal secretions (n=6).
doi:10.1371/journal.pone.0029255.g001
IFN-alpha Controls Influenza A Virus Replication
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Exogenous interferon administration induces antiviral
immunity in the lungs of rhesus macaques
Based on previous experiments in rhesus macaques [13], six
animals with body weights ranging from 7 to 10 kg were
administered 100 ug of pegylated human recombinant IFN-alpha
(PegasysH, Roche Pharmaceuticals) locally and systemically. To
induce the Type I IFN response in the respiratory tract, 25 ug of
exogenous IFN-alpha in 1 mL PBS was administered drop wise
intranasally and 25 ug IFN-alpha in 1 mL PBS was administered
drop-wise intratracheally though a pediatric feeding tube. To
induce the systemic Type I IFN responses, 50 ug of IFN-alpha in
0.5 mL of PBS was injected intramuscularly.
To determine the extent to which antiviral responses were
induced by the IFN-alpha treatment, we monitored changes in the
mRNA levels of two key IFN-stimulated genes, 2–5 oligoadenylate
synthetase (OAS) and myxovirus resistance protein A (MxA).
MxA, a GTPase protein encoded by the MX1 gene with potent
antiviral activity, we chose to monitor MxA because it is a sensitive
and specific biomarker of IFN bioactivity and it is used clinically to
monitor the effect of IFN therapy [14]. The MxA and OAS
mRNA levels of an animal after IFN-alpha administration are
expressed as the increase relative to the average level in two pre-
treatment samples from the same individual animal (Figure 1).
IFN-alpha treatment resulted in increased OAS and MxA mRNA
expression in PBMCs (Figure 1A) and tracheal lavages (Figure 1B)
that peaked 24 hrs after the treatment.
Exogenous IFN-alpha administration 24 hours prior to
virus challenge decreases clinical signs of influenza A
virus infection
To determine the effect of IFN-alpha-induced immunity on
the clinical signs of influenza A virus infection, body tempera-
tures and weights before and after infection were monitored
(Figures 2 and 3). Rectal temperatures were significantly lower in
IFN-alpha-treated monkeys 24 hours after challenge with A/
Memphis/7/01 compared to the control animals (p=0.026,
one-tailed T-test, Figure 2). In addition, by three days post
infection, control animals had a 2.6 fold higher mean weight loss
than the IFN-alpha treated animals (p=0.039, one-tailed T-test,
Figure 3).
Figure 2. Effect of A/Memphis/7/01 inoculation on body temperature. A. Body temperature after influenza virus inoculation relative to the
average of 3 temperatures readings collected before inoculation (mean +/2 SE). B. Difference in body temperature 1 day after influenza virus
inoculation relative to pre-inoculation. (P value for unpaired one-tailed t-test.).
doi:10.1371/journal.pone.0029255.g002
Figure 3. Effect of A/Memphis/7/01 inoculation on body weight. A. Body weight after influenza virus inoculation relative to the average of 3
weights measured before inoculation (mean +/2 SE). B. Difference in body weight 3 days after influenza virus inoculation relative to pre-inoculation.
(P value for unpaired one-tailed t-test.).
doi:10.1371/journal.pone.0029255.g003
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virus challenge blunts influenza A virus replication
To determine the effect of IFN-alpha-induced immunity on the
influenza A virus replication vRNA levels in tracheal secretions
were monitored (Figure 4). Influenza A virus RNA levels were
significantly lower (p=0.031) at 24 hrs PC (Figure 4) and peaked
at a lower level (p=0.012) in IFN-alpha treated animals compared
to control animals (Figure 4).
Discussion
The results of these experiments clearly demonstrate that
systemic and respiratory mucosal administration of IFN-alpha
induces expression of itself (data not shown) and interferon-
stimulated genes in the trachea and blood of rhesus macaques.
Further rhesus macaques treated with IFN-alpha 24 hours prior to
influenza A virus challenge have about a 10-fold reduction in peak
influenza RNA levels in tracheal secretions compared to the
control animals. A log 10 reduction in influenza A virus RNA in
tracheal secretions is the same level of virus suppression that
prophylactic oseltamivir treatment can achieve in rhesus macaques
challenged with A/Memphis/7/01 (H1N1) [10]. Prophylactic
IFN-alpha reduces influenza virus replication as effectively as
prophylactic osletamivir therapy. While the mechanism behind the
effect of exogenous IFN-alpha was not determined, IFN-alpha
administration rapidly induced ISG expression that peaked
around 24 hours. By inoculating the RM with influenza virus at
the peak of the ISG response virus replication was reduced for the
first 24–48 hours of the infection. Thus the induction of innate
antiviral immune responses is the most likely explanation for the
observed effect of prophylactic IFN-alpha administration. It would
be of considerable interest to determine if repeated IFN-alpha
administration could produce more rapid clearance of the virus.
Similarly ferrets treated prophylactically with recombinant ferret
IFN-alpha control influenza replication in the nasal cavity [15].
Thus IFN-alpha induced innate antiviral effector mechanisms
induced prior to infection can blunt seasonal influenza virus
replication in ferrets and monkeys, and likely humans as well.
However, it remains to be seen if IFN-alpha administered
therapeutically after influenza virus infection can suppress virus
replication.
Hundreds of effector genes are upregulated in response to virus
infections, and the key antiviral effector molecule that controls
replication varies with the specific virus [5]. Although it is unclear
which of the ISGs are responsible for suppressing influenza A virus
replication in rhesus macaques after IFN-alpha treatment, there is
some indirect evidence that MxA may play a role. In contrast to
the other ISGs, MxA mRNA expression is suppressed by influenza
virus replication [10]. This result implies the virus is actively
suppressing MxA expression, presumably to avoid the negative
consequences it would have if expression of this gene was
unrestrained. The mechanism by which MxA would control
influenza virus replication in human cells is unknown. Mx1 the
murine homologue of MxA is expressed in the nucleus and
specifically blocks the replication of Orthomyxoviruses [16]. Because
of its location, Mx1 directly inhibits primary transcription of
influenza virus mRNA in the host cell nucleus [17]. In contrast,
human MxA localizes to the smooth endoplasmic reticulum in the
cytoplasm of human cells [18] and thus MxA would not be
expected to affect primary transcription of influenza virus mRNA.
When murine 3T3 cells line are engineered to constitutively
express high levels of MxA and infected with influenza virus, viral
mRNAs are transcribed normally by the virion-associated RNA
polymerase in the nucleus. Viral protein synthesis and genome
Figure 4. Effect of IFN-alpha administration 24 hours prior to
virus challenge on A/Memphis/7/01 influenza virus replication
in the lungs of rhesus macaques. A) Mean influenza A vRNA copy
number (log10 copies/mL) from tracheal lavages of the IFN-alpha
treated (solid line) and untreated animal (dashed line) groups over the
period of observation. B) Comparison of peak vRNA levels in tracheal
lavages after challenge. C) Comparison of 24-hour post-inoculation
vRNA levels in tracheal lavages. (P values for unpaired one-tailed T-
tests.).
doi:10.1371/journal.pone.0029255.g004
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mRNAs direct viral protein synthesis in vitro and appeared to be
efficiently transported to the cell cytoplasm. These results suggest
that in mouse 3T3 cells MxA interferes with either intracytoplas-
mic transport of viral mRNAs, viral protein synthesis, or
translocation of newly synthesized viral proteins to the cell nucleus
[17,19,20]. More recent studies have shown that if MxA is
artificially made to translocate into the nucleus of 3T3 cells, it
binds newly synthesized influenza virus nucleoprotein preventing
viral transcription [17,19,20]. MxA is likely to directly mediate the
observed anti-influenza virus effects. Further study is needed to
confirm that MxA is the key effector molecule that mediates the
ability of IFN-alpha to decrease influenza virus replication in
rhesus macaques and to determine if MxA expression can be
therapeutically manipulated to treat influenza virus infections.
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